Chronic Disease

Engaging consumers in research to improve diabetes and wellness for people who have experienced homelessness

An evidence gap exists between the findings of decades of research to improve diabetes outcomes in low resource communities and persistently poor outcomes and premature mortality among people experiencing homelessness with diabetes compared to their stably housed peers. The Hennepin Healthcare team found that from 2017-2021, Minnesotans who used homeless services had a diabetes mortality […]

Engaging consumers in research to improve diabetes and wellness for people who have experienced homelessness Read More >>

Tobacco Free

Association of Clinicians for the Underserved | Inspired by expert recommendations, Tobacco Free brings you information and resources on the most effective tobacco use interventions for underserved patients, including office systems, motivational interventions and pharmacotherapy. Download Research (Link)

Tobacco Free Read More >>

Waiver Elimination (MAT Act): Notification of Intent to use Schedule III, IV or V Opioid Drugs

Section 1262 of the Consolidated Appropriations Act, 2023 (also known as Omnibus bill), removes the federal requirement for practitioners to submit a Notice of Intent (have a waiver) to prescribe medications, like buprenorphine, for the treatment of opioid use disorder (OUD). With this provision, and effective immediately, SAMHSA will no longer be accepting NOIs (waiver

Waiver Elimination (MAT Act): Notification of Intent to use Schedule III, IV or V Opioid Drugs Read More >>

Scroll to Top